Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab open-label extension in active axial spondyloarthritis
2023-506527-28-00Phase 3Completed
- Sponsor
- UCB
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of bimekizumab in axial spondyloarthritis (axSpA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), sponsored by UCB. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of serious adverse events and 1 more. Started Jul 2024; status: completed.
02
Drugs
bimekizumab
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on 2023-506527-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506527-28-00.